Compounded or brand? The decision has changed
In 2023 this was easy. In 2026 it depends on a number most people have not checked.
The compounded case rested on a price gap that has largely closed. Here is how to decide now.
The analysis
These are not scams — the prices are disclosed. But a patient who does not know the manufacturer-direct programmes exist can pay four to twelve times more for exactly the same medicine. If you take one thing from this database: before you buy any brand-name GLP-1 through a telehealth platform, check LillyDirect and NovoCare first.
July 6, 2026 capture, kept for the record; October 15, 2026 figures are in the pricing database. The two brand lines are the benchmark: Foundayo starts at $149 and brand Zepbound at $299.
What a commitment actually costs you
Providers differ enormously in what happens then. Some refund the unused portion. Some convert you to the month-to-month rate and bill the difference for months already taken. Some refund nothing. This is the single question people most often forget to ask, and it is the one most likely to cost them money.
Dose escalation: the risk the headline price hides
| Provider | Price at higher doses | Risk |
|---|---|---|
| NexLife | Same at every covered dose | None — flat rate |
| Mochi Health | Same at all doses | None |
| Enhance.MD | Same at all doses | None |
| Eden | Same at all doses (compounded) | None on compounded |
| TrimRx | Flat ongoing rate | None |
| Oak Longevity | Flat across dosages | None |
| Shed | Increases at higher doses | Material — model at maintenance |
| MEDVi | $399 → $499 at 10-15mg (July 2026 capture; not re-read) | Material — $1,200/yr swing |
| LillyDirect (brand) | $299 → $449; $699 if you miss the 45-day refill | Material — set a reminder |
The insurance pathway
Coverage is most common through employer-sponsored commercial plans. Zepbound is excluded from Medicare Part D for weight loss and from most state Medicaid programmes. From 1 July 2026, eligible Medicare Part D members can obtain Wegovy at $50/month through the Medicare GLP-1 Bridge, running to 31 December 2027. Expect prior-authorisation paperwork: typically a BMI of 30+, or 27+ with a weight-related condition.
PlushCare ($19.99/month), Found and Mochi will handle that paperwork for you. If you have coverage, that is worth more than any cash discount.
Dose caps: the other thing a low price can hide
How to verify any of this yourself
You should not take our word for a price, and you do not have to. Every figure here can be checked in a few minutes.
- Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
- Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
- Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
- Ask what the highest dose costs. By email or chat, so you have it in writing.
- Ask about early cancellation before you commit to a plan longer than a month.
- Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.
If a provider will not answer questions 4 or 5 in writing, that is itself information.
What to do about it
Three practical steps follow from everything above.
- Check your insurance first. A covered brand prescription with a manufacturer savings card can cost roughly $25 a month, which beats every cash option discussed here.
- Then price the manufacturer directly. LillyDirect and NovoCare sell brand GLP-1s for $149-$449. In our July 2026 capture, some telehealth platforms resold the identical drugs at four to eleven times that.
- Then, and only then, compare compounded programmes — on their ongoing total cost, medication plus any mandatory membership, at the dose you expect to maintain.
Most of the money people lose in this category is lost at step one and step two, before any comparison table is even opened.
Limitations of this analysis
Every page on this site should tell you where it stops being reliable. This one stops here.
Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.
Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.
We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.
Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.
Frequently asked questions
What is the single most useful thing to check?
Your insurance, and then the manufacturer's own direct price. Both are routinely skipped, and both can be worth hundreds of dollars a month.
How current is this?
Brand pricing verified July 12, 2026 against manufacturer sources. NexLife pricing transcribed July 11, 2026. Competitor pricing captured from provider pages and confirmed July 6, 2026, and labelled Reported rather than Verified.
Do you earn commission?
We may earn a commission when readers use certain provider links. That is disclosed in our footer on every page. It does not change any score, ranking or conclusion, and where a commercially-related provider loses a category we say so.
Update history
| Date | What changed |
|---|---|
| July 12, 2026 | Brand pricing re-verified. |
| July 6, 2026 | Provider dataset refreshed. |
Sources
- U.S. Food and Drug Administration — labels, compounding guidance, adverse-event reporting.
- Eli Lilly (LillyDirect) and Novo Nordisk (NovoCare) published self-pay pricing.
- NexLife published program pages, transcribed July 11, 2026.
- Provider pricing dataset — captured from provider pages and confirmed July 6, 2026. Verified.
- Our pricing-verification methodology and source policy.